Cargando…

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection

Detalles Bibliográficos
Autores principales:	Zamarin, Dmitriy, Holmgaard, Rikke, Subudhi, Sumit, Mansour, Mena, Palese, Peter, Merghoub, Taha, Wolchok, Jedd D, Allison, James P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991380/ http://dx.doi.org/10.1186/2051-1426-1-S1-O9

Ejemplares similares

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
por: Zamarin, Dmitriy, et al.
Publicado: (2017)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Exploiting tumor epigenetics to improve oncolytic virotherapy
por: Forbes, Nicole E., et al.
Publicado: (2013)

Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements
por: Jin, Ke-Tao, et al.
Publicado: (2021)

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy
por: Enow, Junior A., et al.
Publicado: (2023)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?
por: Denton, Nicholas L., et al.
Publicado: (2016)

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
por: Wang, Xianwang, et al.
Publicado: (2023)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023)

In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics
por: Berg, David R., et al.
Publicado: (2019)

Targeting tumor vasculature through oncolytic virotherapy: recent advances
por: Toro Bejarano, Marcela, et al.
Publicado: (2015)

Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy?
por: Herbein, Georges, et al.
Publicado: (2020)

Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach
por: Mahasa, Khaphetsi Joseph, et al.
Publicado: (2017)

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
por: Francis, Lily, et al.
Publicado: (2016)

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
por: Bressy, Christian, et al.
Publicado: (2017)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Oncolytic virotherapy – in vivo veritas
por: Kemler, Iris, et al.
Publicado: (2018)

Delivery and Biosafety of Oncolytic Virotherapy
por: Li, Lizhi, et al.
Publicado: (2020)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019)

Progress of oncolytic virotherapy for neuroblastoma
por: Chen, Xiao-Tong, et al.
Publicado: (2022)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy
por: Wang, Xianyao, et al.
Publicado: (2021)

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
por: Zhang, Yalei, et al.
Publicado: (2021)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

Oncolytic virotherapy for advanced liver tumours
por: Chang, Ju-Fang, et al.
Publicado: (2009)

The Practical Consideration of Poliovirus as an Oncolytic Virotherapy
por: Denniston, Elizabeth, et al.
Publicado: (2016)

Measles virus: Background and oncolytic virotherapy
por: Bhattacharjee, Sankhajit, et al.
Publicado: (2018)

Multidisciplinary oncolytic virotherapy for gastrointestinal cancer
por: Fujiwara, Toshiyoshi
Publicado: (2019)

Implications of MicroRNAs in Oncolytic Virotherapy
por: Bofill-De Ros, Xavier, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_avmm1r6oa288l5rlhu6pofjqub